New Clinical Trial Protocol for Thymalfasin-Regulated PRaG Regimen in Advanced Cancers

Advanced refractory solid tumours represent a significant challenge in oncology, often leading to poor prognoses due to resistance to conventional therapies. Current treatment options are frequently limited, highlighting an urgent need for novel and effective strategies. This study protocol outlines a new open-label, prospective, multicentre clinical trial to evaluate the efficacy and safety of a precise thymalfasin-regulated PRaG regimen in these difficult-to-treat cancers.

The PRaG5.0 study is meticulously designed to assess the clinical efficacy and safety of the thymalfasin-regulated PRaG regimen in patients with advanced refractory solid tumours. The primary objective is to determine the objective response rate (ORR), which measures tumour shrinkage or disappearance, in this challenging patient population. Secondary objectives include evaluating progression-free survival (PFS) and overall survival (OS), providing comprehensive insights into the regimen's potential long-term benefits. The study's robust design, involving 120 patients across 10 centres, is intended to provide high-quality evidence on the efficacy and safety profile of this novel combination therapy. Safety will be rigorously monitored, with adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, ensuring a thorough assessment of tolerability. The study aims to compare the observed ORR, PFS, and OS with historical data for similar regimens to determine the added benefit of thymalfasin.